Patents by Inventor Hiroyuki Ebinuma

Hiroyuki Ebinuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220316000
    Abstract: An object of the invention is to provide an optical detection method and a quantification method of a product obtained by amplifying a target nucleic acid contained in a paper piece of a blood spot in a filter paper obtained by blotting blood on a filter paper and then drying the blood using nucleic acid amplification reaction by real-time PCR and to further provide a kit used for the methods. The invention provides a method and a kit which can optically detect and quantify a target nucleic acid from a dried blood spot in a filter paper by real-time PCR without any complicated pretreatment, by adjusting the size of the punched piece of the dried blood spot in a filter paper or the whole blood amount contained in the punched piece, the amount of the PCR reaction reagent, or performing the PCR reaction in a PCR reaction tube closed with a cap.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 6, 2022
    Applicants: SEKISUI MEDICAL CO., LTD., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT
    Inventors: Hiroyuki EBINUMA, Hiroaki INOUE, Toru UCHIYAMA
  • Publication number: 20220267852
    Abstract: An object of the invention is to provide a primer for detecting and quantifying homozygous deletion of the SMN1 gene, the deletion of which causes SMA, using a dried blood spot in a filter paper and a method related to specific detection/quantification of the SMN1 gene using the primer.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 25, 2022
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki EBINUMA, Ikumi SUZUKI
  • Patent number: 11155805
    Abstract: An object of the present invention is to provide an efficient nucleic acid recovery method capable of concentrating a nucleic acid from a sample containing a nucleic acid such that the nucleic acid is usable in gene amplification reaction. To solve the problem, the present inventors have found that by targeting a protein to which a nucleic acid is bound (hereinafter also referred to as a nucleoprotein or a protein-nucleic acid complex) rather than targeting the nucleic acid itself, or specifically, by causing a specific antibody against the protein to act, the nucleic acid can be captured simultaneously with the protein, and thereby completing the present invention. Furthermore, the present inventors have found that if animal cells, bacteria, viruses, etc.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: October 26, 2021
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki Ebinuma, Katsura Uchida
  • Publication number: 20210079456
    Abstract: An object of the present invention is to provide a method for highly sensitively detecting, and a method for quantifying, a mutant gene (mutant allele) contained at a low frequency in a nucleic acid sample containing a wild-type allele. In one-reaction system in which a first-primers set designed to flank a mutation site of a gene of interest is mixed with a second-primers set including an ASP corresponding to the mutation, an amplification product can be obtained from a low-frequency mutant gene, and quantitativeness can be ensured, by including a competitive nucleic acid suppressing an amplification reaction from a wild-type allele of the gene, selecting a certain primer concentration condition, and controlling the cycle numbers of PCR reactions using the first and second-primers sets.
    Type: Application
    Filed: July 25, 2018
    Publication date: March 18, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki EBINUMA, Yuriko TSUKAMOTO
  • Patent number: 10626452
    Abstract: An object of the present invention is to provide a method for accurately and quantitatively discriminating and detecting a wide variety of gene mutations, or particularly, single base substitutions or point mutations. In an ASP for analyzing gene mutations, or particularly, single base substitutions or point mutations, when a non-nucleotide component is added to the 5? end of at least one of the ASP and a primer paired therewith before amplification by PCR and amplification products thereof are separated by ion-exchange chromatography, even the amplification products having the same length can be separated and detected.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: April 21, 2020
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki Ebinuma, Katsura Uchida, Yuriko Tsukamoto
  • Publication number: 20190376057
    Abstract: An object of the present invention is to provide an efficient nucleic acid recovery method capable of concentrating a nucleic acid from a sample containing a nucleic acid such that the nucleic acid is usable in gene amplification reaction. To solve the problem, the present inventors have found that by targeting a protein to which a nucleic acid is bound (hereinafter also referred to as a nucleoprotein or a protein-nucleic acid complex) rather than targeting the nucleic acid itself, or specifically, by causing a specific antibody against the protein to act, the nucleic acid can be captured simultaneously with the protein, and thereby completing the present invention. Furthermore, the present inventors have found that if animal cells, bacteria, viruses, etc.
    Type: Application
    Filed: March 27, 2018
    Publication date: December 12, 2019
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki EBINUMA, Katsura UCHIDA
  • Publication number: 20190203284
    Abstract: An object of the present invention is to provide a method for accurately and quantitatively discriminating and detecting a wide variety of gene mutations, or particularly, single base substitutions or point mutations. In an ASP for analyzing gene mutations, or particularly, single base substitutions or point mutations, when a non-nucleotide component is added to the 5? end of at least one of the ASP and a primer paired therewith before amplification by PCR and amplification products thereof are separated by ion-exchange chromatography, even the amplification products having the same length can be separated and detected.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 4, 2019
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki EBINUMA, Katsura UCHIDA, Yuriko TSUKAMOTO
  • Publication number: 20190032123
    Abstract: An object of the present invention is to provide a novel method for designing a primer ensuring reactivity and discriminatory power in a method for detecting a single base substitution based on an ASP-PCR method and to provide a method for easily detecting multiple point mutations within overlapping amplicons, particularly, two adjacent single base substitutions. The single base substitutions can easily be detected by using a mutant primer in which the base of the third nucleotide from the 3? end corresponds to the base of a mutant nucleotide of a single base substitution contained in a nucleic acid sample, in which the base of the second nucleotide from the 3? end is not complementary to the base of the corresponding nucleotide of the nucleic acid, and in which the bases of the other nucleotides are complementary to the bases of the corresponding nucleotides of the nucleic acid.
    Type: Application
    Filed: March 29, 2017
    Publication date: January 31, 2019
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki EBINUMA, Katsura UCHIDA, Yuriko TSUKAMOTO
  • Publication number: 20180273625
    Abstract: Provided are a method of efficiently producing an sIL-2R antigen in an amount necessary for antibody generation, and a method of producing an anti-sIL-2R antibody using the antigen. Specifically, provided are a method of producing soluble interleukin-2 receptor, including culturing SCC-3 cells and recovering soluble interleukin-2 receptor from a culture of the cells, and a method of producing an anti-soluble interleukin-2 receptor antibody, including immunizing an animal with sIL-2R produced by the method.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 27, 2018
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki EBINUMA, Kengo FUJIMURA
  • Patent number: 9969802
    Abstract: Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: May 15, 2018
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki Ebinuma, Kohei Takubo, Isamu Fukamachi, Saishu Yoshida, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
  • Patent number: 9541550
    Abstract: To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: January 10, 2017
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Kohei Takubo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
  • Patent number: 9442123
    Abstract: Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: September 13, 2016
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventor: Hiroyuki Ebinuma
  • Patent number: 9261443
    Abstract: Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: February 16, 2016
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
  • Publication number: 20160018419
    Abstract: Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.
    Type: Application
    Filed: March 16, 2015
    Publication date: January 21, 2016
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventor: Hiroyuki EBINUMA
  • Patent number: 9097714
    Abstract: To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: August 4, 2015
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki Ebinuma, Kohei Takubo, Masanao Matsuo, Isamu Fukamachi, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
  • Publication number: 20140080158
    Abstract: To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.
    Type: Application
    Filed: May 9, 2012
    Publication date: March 20, 2014
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Kohei Takubo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
  • Publication number: 20140038213
    Abstract: Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.
    Type: Application
    Filed: October 17, 2013
    Publication date: February 6, 2014
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventor: Hiroyuki Ebinuma
  • Publication number: 20130115229
    Abstract: Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested.
    Type: Application
    Filed: July 15, 2011
    Publication date: May 9, 2013
    Applicant: Sekisui Medical Co., Ltd.
    Inventors: Hiroyuki Ebinuma, Kohei Takubo, Isamu Fukamachi, Saishu Yoshida, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
  • Patent number: 8411202
    Abstract: In an automatic gain control circuit comprising a black level detecting unit which detects a black level from a video signal, a white level detecting unit which detects a white level from the video signal, and an analog-to-digital converter which adjusts a dynamic range of the video signal based on a difference value between the black level and the white level, a video signal for adjustment including a black level which indicates a minimum brightness of a video image and a white level which indicates a maximum brightness of the video image is input and the dynamic range is adjusted.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: April 2, 2013
    Assignees: Sanyo Semiconductor Co., Ltd., Semiconductor Components Industries, LLC.
    Inventors: Hirotoshi Mori, Hiroyuki Ebinuma
  • Publication number: 20130029363
    Abstract: To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.
    Type: Application
    Filed: December 15, 2010
    Publication date: January 31, 2013
    Applicant: Sekisui Medical Co., Ltd.
    Inventors: Hiroyuki Ebinuma, Kohei Takubo, Masanao Matsuo, Isamu Fukamachi, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito